SA： 嗯，我们想做的就是打造非常强大的人工智能，叫它 AGI 也好，超级智能也罢，不 管现在流行叫它什么，然后把它部署出去，让它能真正造福人类，让人们能用它来做各种 各样的事情。这事儿呢，在基础设施、产品，当然还有研究方面，都有挺多活儿要干的。 我们想做的就这一件事。 OpenAI 的宏大愿景 主持人： 我们只有 30 分钟，我担心啊，要是把 OpenAI 过去一个月搞的那些合作和发布 会都念一遍，估计这半小时就全用完了，而且我真没夸张。所以，为了省点时间，你们最 近这么多动作，从开发者日上宣布的，到这些基础设施合作，背后到底有个啥宏大的统一 理论？能不能用一句话或者一段话给概括一下？ SA： 我老是搞不定这种历史类比，因为我总会纠结于那些我很在意的不同之处什么的。 我是这么想的：大多数人未来可能就只需要一个 AI 服务，这个服务得在他们生活的方方 面面都有用。所以你会用 ChatGPT，但你又希望它能跟别的服务整合在一起，所以你需 要在 ChatGPT 里面能用上别的 App。我们得有 API 业务，因为你会想用 OpenAI 账号登 录别人做的某个服务，你想要的是那种体验的连续性，希望它一直都懂你、存着 ...

Core Viewpoint - Barclays reports that Anthropic's API business has surpassed OpenAI in both scale and growth rate, significantly contributing to AWS's revenue [1][9][11]. AWS and Anthropic Collaboration - The deep collaboration between AWS and Anthropic is expected to drive substantial revenue growth for AWS, with estimates suggesting that Anthropic could contribute approximately 4% to AWS's quarterly growth by Q4 2025 [3][19]. - Barclays estimates that Anthropic's API revenue will reach $3.9 billion by 2025, with a staggering year-over-year growth of 662% [11][19]. - The report indicates that Anthropic's contribution to AWS's growth is currently around 1%, but this could increase significantly with the launch of Claude 5 and existing inference revenue [3][19]. Revenue Breakdown - In 2025, Anthropic's total API revenue is projected to be $3.9 billion, with direct API revenue accounting for $3.0 billion and indirect revenue at $0.9 billion [4][10]. - AWS is expected to generate $1.6 billion from Anthropic's API, with inference revenue contributing significantly to this figure [4][10]. Market Perception and Growth Potential - The market has not fully recognized the growth potential of AWS's AI capabilities, particularly in relation to its partnership with Anthropic [3][22]. - Analysts predict that AWS's revenue growth in Q4 could exceed market expectations by approximately 2%, driven by Anthropic's contributions [16][17]. AI Development Environment - The rapid growth of AI integrated development environments (IDEs) is a key factor in Anthropic's success, with tools like Cursor and Lovable leveraging Anthropic's Direct API [13][15]. - The AI IDE market is expected to exceed $1 billion in annual recurring revenue (ARR) by 2025, a significant increase from nearly zero in 2024 [15]. Challenges in Collaboration - Despite the benefits of the partnership, there are potential challenges, including complaints about access to Anthropic models via AWS Bedrock and key clients like Cursor considering alternatives such as OpenAI's GPT-5 API [22][26]. - The relationship between AWS and Anthropic may face strains as major clients explore other options, which could impact future revenue contributions [22][26]. Long-term Growth Outlook - AWS is expected to expand its AI computing capacity significantly, with projections of over 1 million H100 equivalent AI capacities by the end of 2025 [20][21]. - The collaboration with Anthropic positions AWS at the forefront of the AI revenue generation trend, despite uncertainties in the broader market [25][26].

Group 1: Company Performance Overview - API business revenue decreased by 23.41% due to industry downturn and active contraction of low-margin trading business [3] - CDMO business achieved over 20% growth with significant margin improvement, now accounting for nearly 40% of total gross profit [6] - Total number of CDMO clients exceeded 650, projected to surpass 700 by year-end [6] Group 2: Market Trends and Opportunities - China's CDMO industry has returned to a healthy growth state after disruptions in 2022 and 2023 [4] - The license-out fees for Chinese innovative drugs rose from tens of billions in 2021-2022 to nearly $50 billion in 2022, with 2023 already exceeding last year's total [3] - The US and China are leading in innovative drug development, creating significant opportunities for the CDMO sector [4] Group 3: Future Projections - CDMO business revenue is expected to reach 6-7 billion by 2030, with a balanced market share between China and the US [11] - The overall industry is anticipated to recover gradually, with a clear bottom observed in 2023 [12] - The average gross margin for CDMO projects is projected to increase from 35%-40% to 45%-55% as project structures optimize [13] Group 4: Product and Service Development - The company has over 1,180 CDMO projects, with 377 commercialized and 803 in clinical stages, reflecting a 35% year-on-year growth [6] - The multi-peptide CDMO business is expanding, with over 60 projects in various stages of development [15] - The company is enhancing its R&D capabilities, with plans to increase CDMO R&D personnel from 900 to over 2,000 by 2030 [16] Group 5: Financial Returns and Shareholder Value - Total cash dividends and buybacks have exceeded $3.2 billion, significantly higher than the total cash raised of $1.458 billion since listing [9] - The company is committed to shareholder returns while ensuring operational and developmental sustainability [10] Group 6: API Business Insights - API prices are stabilizing, with a projected recovery in the market, particularly in the antibiotic sector [17] - The company aims to adjust its product structure, reducing antibiotic reliance and increasing non-antibiotic offerings [18] - The industrial segment of API business is expected to reach 7 billion, focusing on a diverse product portfolio [18] Group 7: International Market Dynamics - Overseas revenue accounted for approximately 40% last year, expected to maintain between 40%-50% in the future [19] - The company maintains a competitive edge in API manufacturing, with expectations of limited impact from potential tariff changes [19]